Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nasacort®
triamcinolone XRG5029 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A - Nasacort® | EXPERIMENTAL | Nasacort® will be sprayed twice in each nostril once every morning |
| Group B - Flixonase® | ACTIVE_COMPARATOR | Flixonase® will be sprayed twice in each nostril once every morning |
| Name | Type | Description |
|---|---|---|
| triamcinolone XRG5029 | DRUG | Pharmaceutical form: spray solution Route of administration: nasal |
| fluticasone | DRUG | Pharmaceutical form: spray solution Route of administration: nasal |
Inclusion criteria: * Females and males ≥18 and ≤50 years old. * Patients with previously diagnosed PAR with a positive skin prick test response to an appropriate allergen performed not earlier than 12 months prior to the Screening visit. * Patients must be clinically symptomatic (rTNSS reflecting ...
Triamcinolone XRG5029 is an investigational small molecule developed by Sanofi for allergic rhinitis. It is a nasal spray formulation studied in adults with perennial allergic rhinitis. The program has completed a Phase 3 trial comparing it with another nasal spray, and no active trials are currently listed.
Triamcinolone XRG5029 is being studied for the treatment of allergic rhinitis, specifically perennial allergic rhinitis in adults. The completed Phase 3 trial enrolled adults aged 18 years and older with this condition. It is an investigational asset and has not been established as an approved treatment.
Triamcinolone XRG5029 targets NR3C1, the glucocorticoid receptor, and acts as an agonist at this receptor. NR3C1 agonism is the mechanism of action for this class of small molecule. This target activity underlies its development as an intranasal therapy for allergic rhinitis.
Triamcinolone XRG5029 is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program for this asset in allergic rhinitis.
Triamcinolone XRG5029 is in Phase 3 development. One Phase 3 trial has been completed, and no active trials are currently listed for the program. It is an investigational drug and is not described as FDA approved.
Triamcinolone XRG5029 has been studied in the completed Phase 3 trial NCT03317015, titled a study to assess efficacy and safety of Nasacort nasal spray compared with Flixonase nasal spray in adults with perennial allergic rhinitis. The trial enrolled 260 participants, was randomized, double blind, and active controlled.